Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Mesothelioma 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 21Oxaliplatin 17Leucovorin 17Bevacizumab 17Irinotecan 13Panitumumab 12Cetuximab 12IFL protocol 9Capecitabine 9pembrolizumab 7Radiotherapy 7Pemetrexed 5Gemcitabine 5labetuzumab 3conatumumab 3Cisplatin 3Carboplatin 3Albumin-Bound Paclitaxel 35,11-methenyltetrahydrohomofolate 3130-nm albumin-bound paclitaxel 3vatalanib 2trametinib 2spartalizumab 2pegfilgrastim 2ganitumab 2encorafenib 2dostarlimab 2Ramucirumab 2Paclitaxel 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rectal Neoplasms × MAC321 × Clear all
NCT00063427 2009-08-21

Study Evaluating MAC-321 in Colorectal Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
45 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡